Overview

• MD Anderson will present what they describe as the first 10-year comparison of SBRT versus surgery at the ASTRO 2025 meeting on Sept. 29.
• At a median 8.3-year follow-up, overall survival was 69% with SBRT versus 66% with video-assisted lobectomy, without a significant difference.
• Lung cancer–specific survival and recurrence-free survival were comparable between the two cohorts.
• Surgery led to more acute treatment-related complications, yet patient-reported quality of life at 10 years was similar.
• The 160-patient trial enrolled operable, node-negative tumors under three centimeters and compared SBRT with VATS lobectomy with mediastinal node removal, and investigators urge multidisciplinary selection rather than universal substitution.